

REMARKS

Currently, claims 1-5, 8, 9, and 14 are pending in the present application. Claims 6, 7, and 12 have been cancelled without prejudice to or disclaimer of the subject matter contained therein. Claims 6 and 7 are cancelled in response to the restriction requirement. Claims 1, 8, and 9 have been amended. Claims 1 and 9 were amended in response to the restriction requirement, while claim 8 was amended to correct a typographical error. No new matter has been added by way of amendment.

The Office Action states that the Applicants are required to elect a single invention selected from:

- Group I, Claims 1-5, 8-9, 12, and 14, drawn to a compound of formula (I) wherein X is pyrimidinyl, corresponding composition and method of use;*
- Group II, Claims 1-5, 7, 9, 12, and 14, drawn to a compound of formula (I) wherein X is pyridinyl, corresponding composition and method of use;*
- Group III, Claims 1-6, 9, 12, and 14, drawn to a compound of formula (I) wherein X is pyrazolyl, corresponding composition and method of use; or*
- Group IV, Claims 1-6, 12, and 14, drawn to a compound of formula (I) wherein X is indazolyl, corresponding composition and method of use.*

Applicants hereby elect the claims of Group I for prosecution in the present case. Claims 1-5, 8, 9, and 14 read on the elected invention.

It is believed that the current application is now in condition for allowance. Early notice to this effect is solicited. If, in the opinion of the Examiner, an interview would expedite prosecution, the Examiner is invited to call the undersigned.

Respectfully submitted,



Kathryn L. Coulter
Attorney for Applicant
Registration No. 45,889

Date: 3/26/2009
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1467
Facsimile: (919) 483-7988